Jefferies

NEW YORK (GenomeWeb) – Nanosphere said after the close of the market on Thursday that it is exploring potential strategic alternatives and has hired Jefferies as an advisor.

NEW YORK (GenomeWeb News) – Investment bank Jefferies today downgraded Myriad Genetics and Cepheid to Hold from Buy.

NEW YORK (GenomeWeb News) – Investment bank Jefferies today upgraded shares of Sequenom to Buy following a survey of US commercial payors that suggests the San Diego-based firm is gaining "meaningful traction" in getting coverage for its MaterniT21 Plus LDT test.

"CMS is the decision-maker here regarding fee schedule placement [of genetic tests] and we are pleased they are recognizing the importance … of having stakeholders provide input on the questions they've asked," said David Mongillo, vice president for policy and medical affairs at the American Clinical Laboratory Association.

The investment firm lowered revenue estimates and the share-price target for Nanosphere following the FDA's denial of the company's Plavix metabolism test.

CFO Roger Moody talked up Nanosphere's test for Plavix metabolism and other tests in the company's pipeline at the Jefferies Global Healthcare Conference.

Sequenom reiterated its plans to launch its T21 test by the end of the year as an LDT, while Agilent is looking to move into the top ranks as a life science instrument vendor.

Gen-Probe sees growth opportunities with its Panther platform and tests for STDs, trichomonas, HPV, and blood screening.

Pages

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.